These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 39211288)

  • 1. CD47-SIRPα signaling-inspired engineered monocytes for preventing the progression of atherosclerotic plaques.
    Xia Q; Liu F; Zhou Y; Yang G; Li F; Liang T; Liu J; Li W; Huang Y; Zhu C
    Mater Today Bio; 2024 Oct; 28():101178. PubMed ID: 39211288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Clustering' SIRPα into the plasma membrane lipid microdomains is required for activated monocytes and macrophages to mediate effective cell surface interactions with CD47.
    Ha B; Lv Z; Bian Z; Zhang X; Mishra A; Liu Y
    PLoS One; 2013; 8(10):e77615. PubMed ID: 24143245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of myeloid cell-specific SIRPα, but not CD47, attenuates inflammation and suppresses atherosclerosis.
    Singla B; Lin HP; Ahn W; Xu J; Ma Q; Sghayyer M; Dong K; Cherian-Shaw M; Zhou J; Huo Y; White J; Csányi G
    Cardiovasc Res; 2022 Dec; 118(15):3097-3111. PubMed ID: 34940829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Phagocytosis in the Pro-Inflammatory Response in LDL-Induced Foam Cell Formation; a Transcriptome Analysis.
    Orekhov AN; Nikiforov NG; Sukhorukov VN; Kubekina MV; Sobenin IA; Wu WK; Foxx KK; Pintus S; Stegmaier P; Stelmashenko D; Kel A; Gratchev AN; Melnichenko AA; Wetzker R; Summerhill VI; Manabe I; Oishi Y
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nano-bioconjugate modified with anti-SIRPα antibodies and antisense oligonucleotides of mTOR for anti-atherosclerosis therapy.
    Liu Y; Huang Q; He M; Chen T; Chu X
    Acta Biomater; 2024 Mar; 176():356-366. PubMed ID: 38160854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells.
    Bian Z; Shi L; Guo YL; Lv Z; Tang C; Niu S; Tremblay A; Venkataramani M; Culpepper C; Li L; Zhou Z; Mansour A; Zhang Y; Gewirtz A; Kidder K; Zen K; Liu Y
    Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5434-43. PubMed ID: 27578867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect.
    Sha X; Dai Y; Chong L; Wei M; Xing M; Zhang C; Li J
    J Nanobiotechnology; 2022 Dec; 20(1):506. PubMed ID: 36456996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.
    Lv Z; Bian Z; Shi L; Niu S; Ha B; Tremblay A; Li L; Zhang X; Paluszynski J; Liu M; Zen K; Liu Y
    J Immunol; 2015 Jul; 195(2):661-71. PubMed ID: 26085683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
    Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
    Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the CD47-SIRPα interaction reverses the disease phenotype in a polycythemia vera mouse model.
    Lysenko V; Schürch PM; Tuzlak S; van Wijk NW; Kovtonyuk LV; Becher B; Manz MG; Kreutmair S; Theocharides APA
    Leukemia; 2023 Jun; 37(6):1277-1286. PubMed ID: 37095207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages.
    Laguna-Fernandez A; Checa A; Carracedo M; Artiach G; Petri MH; Baumgartner R; Forteza MJ; Jiang X; Andonova T; Walker ME; Dalli J; Arnardottir H; Gisterå A; Thul S; Wheelock CE; Paulsson-Berne G; Ketelhuth DFJ; Hansson GK; Bäck M
    Circulation; 2018 Oct; 138(16):1693-1705. PubMed ID: 29739755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of CD47 from Schwann cells and macrophages hastens myelin disruption/dismantling and scavenging in Schwann cells and augments myelin debris phagocytosis in macrophages.
    Gitik M; Elberg G; Reichert F; Tal M; Rotshenker S
    J Neuroinflammation; 2023 Oct; 20(1):243. PubMed ID: 37872624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophages show higher levels of engulfment after disruption of
    Hayes BH; Tsai RK; Dooling LJ; Kadu S; Lee JY; Pantano D; Rodriguez PL; Subramanian S; Shin JW; Discher DE
    J Cell Sci; 2020 Mar; 133(5):. PubMed ID: 31964705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HDAC6 improves anti-CD47 immunotherapy.
    Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
    J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.
    Xiao A; Akilov OE
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
    Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
    J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.